{
    "ticker": "TYRA",
    "name": "Tyra Biosciences, Inc.",
    "description": "Tyra Biosciences, Inc. is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases. Founded in 2020, Tyra leverages its proprietary drug discovery platform to identify and develop small molecule therapeutics that target specific genetic mutations in tumors, with the aim of providing more effective and personalized treatment options. The company's lead product candidates are designed to address unmet medical needs in oncology, particularly for patients whose tumors harbor specific mutations that have been difficult to treat with existing therapies. Tyra's experienced team of scientists and industry veterans is dedicated to advancing its pipeline through rigorous research, clinical development, and strategic partnerships. The company is committed to improving patient outcomes and transforming the landscape of cancer treatment through its innovative approach to drug discovery and development. With a focus on precision medicine, Tyra aims to empower patients with therapies that not only target the tumor but also minimize side effects associated with traditional cancer treatments.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2020",
    "website": "https://www.tyrabio.com",
    "ceo": "Luca Giubellino",
    "social_media": {
        "twitter": "https://twitter.com/TyraBiosciences",
        "linkedin": "https://www.linkedin.com/company/tyra-biosciences/"
    },
    "investor_relations": "https://investors.tyrabio.com",
    "key_executives": [
        {
            "name": "Luca Giubellino",
            "position": "CEO"
        },
        {
            "name": "Michael Kauffman",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Therapeutics",
            "products": [
                "TYRA-300",
                "TYRA-200"
            ]
        }
    ],
    "seo": {
        "meta_title": "Tyra Biosciences, Inc. | Precision Oncology Solutions",
        "meta_description": "Explore Tyra Biosciences, Inc., a leader in precision oncology focused on developing innovative therapies for cancer treatment. Learn about our mission and pipeline.",
        "keywords": [
            "Tyra Biosciences",
            "Biotechnology",
            "Cancer Therapy",
            "Oncology",
            "Precision Medicine",
            "Tyra-300",
            "Tyra-200"
        ]
    },
    "faq": [
        {
            "question": "What does Tyra Biosciences focus on?",
            "answer": "Tyra Biosciences focuses on developing innovative therapies for cancer and other serious diseases using precision medicine."
        },
        {
            "question": "Who is the CEO of Tyra Biosciences?",
            "answer": "Luca Giubellino is the CEO of Tyra Biosciences, Inc."
        },
        {
            "question": "Where is Tyra Biosciences headquartered?",
            "answer": "Tyra Biosciences is headquartered in San Diego, California, USA."
        },
        {
            "question": "What are Tyra's main product candidates?",
            "answer": "Tyra's main product candidates include TYRA-300 and TYRA-200."
        },
        {
            "question": "When was Tyra Biosciences founded?",
            "answer": "Tyra Biosciences was founded in 2020."
        }
    ],
    "competitors": [
        "ARNA",
        "CRSP",
        "NVTA",
        "BMRN"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "MRNA"
    ]
}